top of page

Time to Diagnosis and Earlier Detection

12 months


Mayo Clinic


PF is a progressive and fatal lung disease. Most patients are referred to pulmonary physicians and other experts late in the course of their disease. Clinical intervention at advanced disease stages is less effective because the fibrosis in the lungs has developed and progressed. 

A three-pronged approach to combat this cycle includes raising awareness of the disease (especially how to identify possible PF symptoms); understanding the current PF diagnostic journey and defining a more effective one; and developing remote diagnostic tools to facilitate early detection. This study will utilize data and analytics to define the current diagnostic journey and impact of existing therapies. It will also explore remote diagnostic tools to facilitate earlier and more accurate detection. 

Andrew H. Limper, MD, serves as the overall Director of this program. Dr. Limper is Associate Dean of Practice Transformation and Annenberg Professor of Pulmonary Medicine at Mayo Clinic. 

Dr. Limper co-authored an article assessing the impact of antifibrotic medications to patient lives post hospitalization. “Outcomes for Hospitalized Patients with Idiopathic Pulmonary Fibrosis Treated with Antifibrotic Medications” was published in BMC Pulmonary Medicine. can found in the Publications section of this website or by clicking here.

Improving Timely Diagnosis

Timely and accurate diagnosis for Interstitial Lung Diseases (ILDs) remains a challenge despite scientific advancements and increased information sharing online.

Influence of Inhaled Exposures in PF

Interstitial Lung Diseases (ILDs) are associated with inhaled environmental and occupational exposures, including air pollution, second-hand smoke, vapors, gases, dusts, and fumes.

Innovation in PF

The Innovation Challenge is one of Three Lakes Foundation’s strategies for accelerating innovation in a space that has not seen significant advances occurring in decades.

Additional Programs

bottom of page